TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
1.125
+0.015 (1.35%)
Oct 12, 2026, 12:23 PM EDT - Market open
TELA Bio Revenue
TELA Bio had revenue of $19.29M in the quarter ending June 30, 2026, a decrease of -4.49%. This brings the company's revenue in the last twelve months to $79.91M, up 6.09% year-over-year. In the year 2025, TELA Bio had annual revenue of $80.28M with 15.84% growth. That makes TELA Bio the 24,363rd largest company in the world by revenue and 3,449th in the United States.
Revenue (ttm)
$79.91M
Revenue Growth
+6.09%
P/S Ratio
0.64
Revenue / Employee
$366,550
Employees
218
Market Cap
50.79M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 80.28M | 10.98M | 15.84% |
| Dec 31, 2024 | 69.30M | 10.85M | 18.56% |
| Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
| Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
| Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
| Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
| Dec 31, 2019 | 15.45M | 7.17M | 86.68% |
| Dec 31, 2018 | 8.27M | 4.03M | 94.91% |
| Dec 31, 2017 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xtant Medical Holdings | 109.53M |
| CVRx, Inc. | 61.19M |
| SANUWAVE Health | 44.02M |
| Myomo | 43.26M |
| Rapid Micro Biosystems | 35.18M |
| QT Imaging Holdings | 26.43M |
| Sensus Healthcare | 17.51M |
| Nano-X Imaging | 15.63M |
TELA News
- 7 days ago - Tela Bio gets FDA clearance for Liora Monofilament Scaffold - TheFly
- 7 days ago - TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement - GlobeNewsWire
- 17 days ago - Craig-Hallum bullish on Tela Bio, initiates with a Buy - TheFly
- 17 days ago - Tela Bio initiated with a Buy at Craig-Hallum - TheFly
- 4 weeks ago - TELA Bio Proxy statement: Proxy filing - Filings
- 5 weeks ago - TELA Bio Proxy statement: Proxy filing - Filings
- 6 weeks ago - Tela Bio COO, CFO Roberto Cuca steps down - TheFly
- 6 weeks ago - TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative - GlobeNewsWire